Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study

Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study

(1) Background: It is well-established that coronavirus disease-2019 (COVID-19) is highly pro-inflammatory, leading to activation of the coagulation cascade. COVID-19-induced hypercoagulability is associated with adverse outcomes and mortality. Current guidelines recommend that hospitalized COVID-19...

Full description

Bibliographic Details
Main Authors: Karolina Akinosoglou, Christos Savopoulos, Abraham Pouliakis, Charalampos Triantafyllidis, Eleftherios Markatis, Foteini Golemi, Angelos Liontos, Charikleia Vadala, Ilias C. Papanikolaou, Vasiliki Dimakopoulou, Panagiotis Xarras, Katerina Varela, Georgia Kaiafa, Athanasios Mitsianis, Anastasia Chatzistamati, Efthalia Randou, Spyridon Savvanis, Maria Pavlaki, Georgios Efraimidis, Vasileios Samaras, Dimitrios Papazoglou, Alexandra Konstantinidou, Periklis Panagopoulos, Haralampos Milionis, on behalf of the INTERACT Study Group
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Viruses
Subjects:
COVID-19
SARS-CoV-2
coronavirus
thrombosis
thromboprophylaxis
low molecular weight heparins
Online Access:https://www.mdpi.com/1999-4915/14/4/767

Internet

https://www.mdpi.com/1999-4915/14/4/767

Similar Items